Amedisys Inc. (AMED) Short Interest Update
Amedisys Inc. (NASDAQ:AMED) was the target of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 1,114,930 shares, a decrease of 60.2% from the September 15th total of 2,803,524 shares. Approximately 3.4% of the shares of the company are sold short. Based on an average daily trading volume, of 227,857 shares, the short-interest ratio is presently 4.9 days.
Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Amedisys by 1.1% in the second quarter. Vanguard Group Inc. now owns 3,106,088 shares of the company’s stock valued at $156,795,000 after buying an additional 33,785 shares during the last quarter. BlackRock Fund Advisors boosted its position in Amedisys by 1.3% in the second quarter. BlackRock Fund Advisors now owns 1,912,761 shares of the company’s stock valued at $96,556,000 after buying an additional 23,831 shares during the last quarter. State Street Corp boosted its position in Amedisys by 4.6% in the second quarter. State Street Corp now owns 718,753 shares of the company’s stock valued at $36,278,000 after buying an additional 31,770 shares during the last quarter. Renaissance Technologies LLC boosted its position in Amedisys by 81.1% in the first quarter. Renaissance Technologies LLC now owns 630,901 shares of the company’s stock valued at $30,498,000 after buying an additional 282,600 shares during the last quarter. Finally, BlackRock Group LTD boosted its position in Amedisys by 5.3% in the first quarter. BlackRock Group LTD now owns 553,056 shares of the company’s stock valued at $26,736,000 after buying an additional 27,998 shares during the last quarter. Hedge funds and other institutional investors own 91.45% of the company’s stock.
A number of equities research analysts have recently commented on AMED shares. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. Zacks Investment Research cut shares of Amedisys from a “hold” rating to a “sell” rating in a report on Monday, July 11th. Jefferies Group reaffirmed a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Mizuho cut shares of Amedisys from a “buy” rating to a “neutral” rating and reduced their target price for the company from $57.00 to $55.00 in a report on Wednesday, August 3rd. Finally, Stephens started coverage on shares of Amedisys in a report on Thursday, June 16th. They issued an “equal weight” rating and a $55.00 target price for the company. Seven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $51.75.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/14/amedisys-inc-amed-short-interest-update-2.html
Amedisys (NASDAQ:AMED) opened at 45.55 on Friday. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of 39.85 and a beta of 0.96. Amedisys has a 1-year low of $31.16 and a 1-year high of $55.16. The firm’s 50-day moving average is $47.84 and its 200-day moving average is $49.84.
Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, August 2nd. The company reported $0.42 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.42. The firm earned $360 million during the quarter, compared to analysts’ expectations of $353.07 million. Amedisys had a net margin of 2.78% and a return on equity of 12.17%. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.43 EPS. On average, equities analysts anticipate that Amedisys will post $1.69 EPS for the current year.
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.